Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

Daraxonrasib shows antitumour activity in patients with previously treated metastatic RAS-mutated NSCLC
Дата публикации: 10-09-2026 07:09:00

Findings from the RMC-6236-001 study

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer018.1416-09-2026
2Perioperative durvalumab continues to show clinical benefit in patients with resectable stage IIA to IIIB NSCLC09.2717-09-2026
3FDA approves landmark pancreatic cancer drug that's shown to improve survival07.926-08-2026
4Perioperative durvalumab plus FLOT improves OS in patients with resectable gastric or GEJ adenocarcinoma09.2215-09-2026
5Comprehensive genomic profiling with subsequent molecularly guided therapy improves outcomes over platinum-based chemotherapy in previously untreated, unfavourable CUP016.4122-09-2026
6EMA recommends extension of therapeutic indications for teclistamab08.3611-09-2026
7Early signs of progress in osteosarcoma research01010-09-2026
8Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases0703-07-2026
9В РАН рассказали о борьбе с раком посредством клеток, помогающих опухоли расти0027-08-2019

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 15.88. Источник: www.esmo.org.